NeuroPace (NASDAQ:NPCE – Get Free Report) announced its quarterly earnings results on Tuesday. The company reported ($0.26) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.29) by $0.03, Briefing.com reports. The firm had revenue of $19.26 million during the quarter, compared to the consensus estimate of $18.30 million. NeuroPace had a negative return on equity of 173.62% and a negative net margin of 45.61%. The firm’s quarterly revenue was up 16.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.36) earnings per share. NeuroPace updated its FY 2024 guidance to EPS.
NeuroPace Trading Down 12.5 %
Shares of NPCE traded down $0.91 on Wednesday, hitting $6.37. 474,653 shares of the stock traded hands, compared to its average volume of 109,293. NeuroPace has a 1 year low of $4.21 and a 1 year high of $18.15. The firm has a market capitalization of $183.25 million, a P/E ratio of -6.18 and a beta of 1.80. The stock’s 50 day moving average is $7.13 and its two-hundred day moving average is $10.97. The company has a quick ratio of 5.56, a current ratio of 6.43 and a debt-to-equity ratio of 4.05.
Analyst Upgrades and Downgrades
A number of equities research analysts recently weighed in on NPCE shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $18.00 price target on shares of NeuroPace in a research report on Wednesday. Wells Fargo & Company lowered their price objective on shares of NeuroPace from $20.00 to $15.00 and set an “overweight” rating on the stock in a research report on Wednesday. Finally, Morgan Stanley reduced their target price on shares of NeuroPace from $9.50 to $8.00 and set an “equal weight” rating for the company in a report on Monday, July 15th. One investment analyst has rated the stock with a hold rating and six have issued a buy rating to the company. According to data from MarketBeat, NeuroPace currently has a consensus rating of “Moderate Buy” and an average price target of $14.00.
NeuroPace Company Profile
NeuroPace, Inc operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely.
Featured Articles
- Five stocks we like better than NeuroPace
- Insider Trading – What You Need to Know
- Brinker International’s Price Dip is an Appetizing Entry Point
- Breakout Stocks: What They Are and How to Identify Them
- 3 Stocks That Could Beat the September Blues
- 3 Monster Growth Stocks to Buy Now
- Canopy Growth Stock: Can It Sustain Recent Gains?
Receive News & Ratings for NeuroPace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroPace and related companies with MarketBeat.com's FREE daily email newsletter.